The DIGICORE Breast Cancer Working Group’s first collaborative study shows that reducing paclitaxel dose intensity during neoadjuvant therapy is common across European centers and can meaningfully affect treatment response in triple negative breast cancer. By pooling real world data from multiple institutions, the group was able to identify clinically relevant patterns that would not have been visible within single center datasets. This work demonstrates how coordinated data sharing and harmonized analytics can generate robust evidence on treatment delivery and outcomes. It also establishes a foundation for future multinational studies aimed at improving the quality and personalization of cancer care.
DOI: 10.1016/j.esmorw.2025.100158